Study of Apatinib in Patients With Differentiated Thyroid Cancer

Thyroid Cancer Clinical Trial

Official title:

Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131（131I）-Refractory/Resistant Differentiated Thyroid Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02731352
• Other study ID #: Ahead-T301
• Status: Completed
• Phase: Phase 2
• Start date: March 11, 2016
• Est. completion date: February 28, 2021

Study information

• Verified date: August 2021
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 28, 2021
• Est. primary completion date: February 27, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hurthle cells, poorly differentiated carcinoma). At least one measurable lesion (helical CT scan long diameter =10mm, meet the requirements of the standard Response Evaluation Criteria In Solid Tumors(RESCIST) version 1.1);

2. Disease progression within 14 months before inclusion;

3. Subjects must be 131I-refractory / resistant as defined by at least one of the following;

• Lesions that do not demonstrate iodine uptake on any radioiodine scan

• Subjects received a single radioactive iodine therapy within 12 months (= 3.7 Giga Becquerel (GBq) [= 100 millicurie (mCi) ]) and target lesion disease progression

• Every two radioactive iodine treatment interval <12 months, doses = 3.7 GBq [=100 mCi], disease progress more than 12 months after at least once iodine therapy;

• Received a total dose of radioactive iodine therapy = 22.2 GBq (= 600 mCi)

4. main organs function is normal;

5. Eastern Cooperative Oncology Group(ECOG)Performance Status(PS) :0-2;

6. An expected survival of = 3 months;

7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug;

8. Patient has to voluntarily join the study and sign the Informed Consent Form for the study;

Exclusion Criteria:

1. Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma);

2. Received VEGFR inhibitor treatment within 1 month;

3. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassII; II-level arrhythmia (including QT interval prolongation, for man = 450 ms, for woman = 470 ms) together with Class II cardiac dysfunction;

4. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);

5. Subjects with high gastrointestinal bleeding risk, including the following conditions:

local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 3 months;

6. Abnormal Coagulation (INR>1.5?APTT>1.5 UNL), with tendency of bleed;

7. Received anti-thyroid cancer chemotherapy treatment (allows the use of low-dose chemotherapy with radiation sensitizer) or thalidomide(or derivative) therapy;

8. Pregnant or lactating women;

9. Other conditions regimented at investigators' discretion.

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Drug:
• Apatinib
Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.
• Apatinib
Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Peking

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease control rate (DCR)	Disease control rate	An expected average of 8 weeks
Primary	Objective response rate (ORR)	Objective response rate	An expected average of 8 weeks
Secondary	Progression free survival (PFS)	progression free survival	Up to approximately 43 months
Secondary	Overall survival (OS)	overall survival	Up to approximately 48 months